- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01060059
Exenatide and Basal Insulins Use in the Real Setting: an Observational Study in Patients With Type 2 Diabetes
EBIRIOS - Exenatide and Basal Insulins Use in the Real Setting: an Italian Observational Study in Patients With Type 2 Diabetes and Secondary Failure of Oral Antihyperglycemic Treatment
Although the efficacy and safety profile of exenatide has been well established, few data exist on the real world results of exenatide treatment in specific populations and clinical settings. This study is intended to fill this gap through observing and collecting prospective data from a population of Italian patients initiating treatment with either exenatide or basal insulin formulations after failure to achieve glycemic control with oral antihyperglycemic agents (OHA).
Observational studies represent noninterventional research; therefore, this study does not involve randomization of patients to particular comparator arms or therapies. The term "noninterventional" means that the healthcare providers decisions regarding the proper treatment and care of the patient are made in the course of normal clinical practice. Patients enrolled in this study are enrolling for the collection of their data on observations made during normal clinical practice.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Acquaviva delle Fonti, Italy
- Research Site
-
Anzio, Italy
- Research Site
-
Bassano del Grappa, Italy
- Research Site
-
Bologna, Italy
- Research Site
-
Brindisi, Italy
- Research Site
-
Cagliari, Italy
- Research Site
-
Campi Salentina, Italy
- Research Site
-
Casarano, Italy
- Research Site
-
Caserta, Italy
- Research Site
-
Cesena, Italy
- Research Site
-
Chieri, Italy
- Research Site
-
Cisternino, Italy
- Research Site
-
Copertino, Italy
- Research Site
-
Cremona, Italy
- Research Site
-
Distretto Vittoria, Italy
- Research Site
-
Fermo, Italy
- Research Site
-
Ferrara, Italy
- Research Site
-
Fidenza, Italy
- Research Site
-
Firenze, Italy
- Research Site
-
Forlì, Italy
- Research Site
-
Genova, Italy
- Research Site
-
Germaneto, Italy
- Research Site
-
Lecce, Italy
- Research Site
-
Livorno, Italy
- Research Site
-
Lucca, Italy
- Research Site
-
Manfredonia (Le), Italy
- Research Site
-
Mariano Comense, Italy
- Research Site
-
Messina, Italy
- Research Site
-
Milano, Italy
- Research Site
-
Monza, Italy
- Research Site
-
Napoli, Italy
- Research Site
-
Novara, Italy
- Research Site
-
Olbia, Italy
- Research Site
-
Palermo, Italy
- Research Site
-
Palmi, Italy
- Research Site
-
Parma, Italy
- Research Site
-
Pavia, Italy
- Research Site
-
Pisa, Italy
- Research Site
-
Potenza, Italy
- Research Site
-
Rimini, Italy
- Research Site
-
Roma, Italy
- Research Site
-
Rossano Scalo, Italy
- Research Site
-
Salerno, Italy
- Research Site
-
San Giovanni Rotondo, Italy
- Research Site
-
Schio, Italy
- Research Site
-
Sesto San Giovanni, Italy
- Research Site
-
Sienna, Italy
- Research Site
-
Treviso, Italy
- Research Site
-
Trieste, Italy
- Research Site
-
Varese, Italy
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Are inadequately controlled with single or multiple OHA as evidenced by an HbA1c > 7.0%
- Have presented during the routine course of care and, together with their physician, have decided to initiate treatment with either exenatide twice daily or conventional insulin therapy with basal insulin (insulin glargine, detemir, protaminated insulin lispro, protaminated human insulin) added to the existing treatment with OHA
- Have not been treated with GLP-1 receptor agonist for more than 7 consecutive days within 3 months before entering the study
- Have not been treated with insulins for more than 7 consecutive days within last 3 months or more than 3 months in the course of the disease
- Are not simultaneously participating in another study which includes an investigational drug or procedure at study entry
- Have been fully informed and given their written consent for use of their data
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
exenatide
The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with exenatide.
|
subcutaneous injection, 5mcg or 10mcg, twice a day
Other Names:
|
basal insulin
The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with basal insulin.
|
subcutaneous injection, dosing according to physician's clinical judgment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Patients Who Achieved Glycemic Target of HbA1c ≤ 7.0% With Minimal Weight Gain (≤ 1 Kg) at Month 12.
Time Frame: Baseline, Month 12
|
Percentage of patients who achieved glycemic target of HbA1c ≤ 7.0% with minimal weight gain (≤ 1 Kg) at month 12.
|
Baseline, Month 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in HbA1c From Baseline to Month 12
Time Frame: Baseline, Month 12
|
Changes in HbA1c from Baseline to Month 12
|
Baseline, Month 12
|
Changes in Fasting Blood Glucose From Baseline to Month 12
Time Frame: Baseline, Month 12
|
Changes in Fasting Blood Glucose From Baseline to Month 12
|
Baseline, Month 12
|
Percentage of Patients With HbA1c Reduction From Baseline >= 1.0% at Month 12
Time Frame: Baseline, Month 12
|
Percentage of Patients with HbA1c Reduction from Baseline >= 1.0% at Month 12
|
Baseline, Month 12
|
Percentage of Patients Achieving HbA1c Concentration <=7.0% at Month 12
Time Frame: Month 12
|
Percentage of Patients Achieving HbA1c Concentration <=7.0% at Month 12
|
Month 12
|
Percentage of Patients Achieving HbA1c Concentration <6.5% at Month 12
Time Frame: Month 12
|
Percentage of Patients Achieving HbA1c Concentration <6.5% at Month 12
|
Month 12
|
Changes in Weight From Baseline to Month 12
Time Frame: Baseline, Month 12
|
Changes in Weight From Baseline to Month 12
|
Baseline, Month 12
|
Percentage of Patients Achieving a Weight Decrease >=3% Between Baseline and Month 12
Time Frame: Baseline, Month 12
|
Percentage of Patients Achieving a Weight Decrease >=3% between Baseline and Month 12
|
Baseline, Month 12
|
Percentage of Patients Achieving a Weight Decrease >=5% Between Baseline and Month 12
Time Frame: Baseline, Month 12
|
Percentage of Patients Achieving a Weight Decrease >=5% between Baseline and Month 12
|
Baseline, Month 12
|
Changes in Fasting Total Cholesterol Between Baseline and Month 12
Time Frame: Baseline, Month 12
|
Changes in Fasting Total Cholesterol Between Baseline and Month 12
|
Baseline, Month 12
|
Changes in Fasting HDL Between Baseline and Month 12
Time Frame: Baseline, Month 12
|
Changes in Fasting HDL Between Baseline and Month 12
|
Baseline, Month 12
|
Changes in Fasting LDL Between Baseline and Month 12
Time Frame: Baseline, Month 12
|
Changes in Fasting LDL Between Baseline and Month 12
|
Baseline, Month 12
|
Changes in Fasting Triglycerides Between Baseline and Month 12
Time Frame: Baseline, Month 12
|
Changes in Fasting Triglycerides Between Baseline and Month 12
|
Baseline, Month 12
|
Changes in Diastolic Blood Pressure Between Baseline and Month 12
Time Frame: Baseline, Month 12
|
Changes in Diastolic Blood Pressure Between Baseline and Month 12
|
Baseline, Month 12
|
Changes in Systolic Blood Pressure Between Baseline and Month 12
Time Frame: Baseline, Month 12
|
Changes in Systolic Blood Pressure Between Baseline and Month 12
|
Baseline, Month 12
|
Percentage of Patients With Hypoglycemia Episodes Between Baseline and Month 12
Time Frame: Baseline to Month 12
|
Percentage of patients with Hypoglycemia Episodes Between Baseline and Month 12. All episodes consistent with hypoglycemia with or without a confirmatory blood glucose reading were collected. |
Baseline to Month 12
|
Factors of Gender, Baseline Presence of Medical Conditions, and Previous Gastrointestinal Symptoms Associated With Treatment Choice at Baseline
Time Frame: baseline
|
Number of patients per arm who were evaluated in 3 factors at baseline (gender, presence of medical conditions, and previous gastrointestinal symptoms) were analyzed for association with treatment choice at baseline.
A total of 12 factors were evaluated.
A multivariate logistic regression model using the full analysis set (FAS) population was performed for each of the factors to determine if exenatide treatment was more likely to be initiated in the presence of the specific factor.
|
baseline
|
Factor of 1 Percent (%) Higher Baseline HbA1c Associated With Treatment Choice at Baseline
Time Frame: baseline
|
Factor of 1% higher baseline HbA1c (from most recent HbA1c) was analyzed for association with treatment choice at baseline.
A total of 12 factors were evaluated.
A multivariate logistic regression model using the full analysis set (FAS) population was performed for each of the factors to determine if exenatide treatment was more likely to be initiated in the presence of the specific factor.
HbA1c was measured as a percent of normal (%).
|
baseline
|
Factor of Longer Duration of Diabetes Associated With Treatment Choice at Baseline
Time Frame: baseline
|
The Factor of longer duration of diabetes at baseline (diagnosed 1 year longer) was analyzed for association with treatment choice at baseline.
A total of 12 factors were evaluated.
A multivariate logistic regression model using the full analysis set (FAS) population was performed for each of the factors to determine if exenatide treatment was more likely to be initiated in the presence of the specific factor.
Duration of diabetes was measured in years since the date of diabetes diagnosis.
|
baseline
|
Factor of Older Age Associated With Treatment Choice at Baseline
Time Frame: baseline
|
Older age (1 year older) was analyzed for association with treatment choice at baseline.
A total of 12 factors were evaluated.
A multivariate logistic regression model using the full analysis set (FAS) population was performed for each of the factors to determine if exenatide treatment was more likely to be initiated in the presence of the specific factor.
Age was measured in years.
|
baseline
|
Factor of Higher Body Mass Index (BMI) Associated With Treatment Choice at Baseline
Time Frame: baseline
|
Factor of higher body mass index (BMI) (1 kilogram per meter squared (kg/m^2) higher) was analyzed for association with treatment choice at baseline.
A total of 12 factors were evaluated.
A multivariate logistic regression model using the full analysis set (FAS) population was performed for each of the factors to determine if exenatide treatment was more likely to be initiated in the presence of the specific factor.
BMI measured as kg/m^2.
|
baseline
|
Factor of Greater Height Associated With Treatment Choice at Baseline
Time Frame: baseline
|
Factor of greater height (1 centimeter higher) was analyzed for association with treatment choice at baseline.
A total of 12 factors were evaluated.
A multivariate logistic regression model using the full analysis set (FAS) population was performed for each of the factors to determine if exenatide treatment was more likely to be initiated in the presence of the specific factor.
Height was measured in centimeters (cm) .
|
baseline
|
Factors of Higher Creatinine, Higher Fasting High Density Lipoprotein (HDL) Cholesterol, Higher Fasting Cholesterol, and Higher Fasting Triglycerides Which Were Associated With Treatment Choice at Baseline
Time Frame: baseline
|
Factors of higher creatinine: 1 milligram per deciliter higher (mg/dL) and higher fasting lipids (HDL cholesterol: 1 mg/dL higher; total cholesterol: 1 mg/dL higher; triglycerides: 1 mg/dL higher) were analyzed for association with treatment choice at baseline.
A total of 12 factors were evaluated.
A multivariate logistic regression model using the full analysis set (FAS) population was performed for each of the factors to determine if exenatide treatment was more likely to be initiated in the presence of the specific factor.
Creatinine and fasting lipids were measured in milligrams per deciliter (mg/dL).
|
baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: James Malone, MD, Eli Lilly and Company
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H8O-IT-B014
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
-
Newsoara Biopharma Co., Ltd.RecruitingT2DM (Type 2 Diabetes Mellitus)China
Clinical Trials on exenatide
-
AstraZenecaEli Lilly and CompanyCompletedType 2 Diabetes MellitusUnited States
-
AstraZenecaCompletedType 2 Diabetes MellitusCanada, United States
-
AstraZenecaEli Lilly and CompanyCompletedType 2 Diabetes MellitusKorea, Republic of, China, Japan, Taiwan, India
-
AstraZenecaCompletedDiabetes Mellitus, Type 2United States
-
Beijing Chao Yang HospitalCompleted
-
AstraZenecaCelerionCompleted
-
AstraZenecaEli Lilly and CompanyCompletedType 2 Diabetes MellitusKorea, Republic of, Mexico, Germany, Greece, Argentina, India, Australia
-
AstraZenecaEli Lilly and CompanyCompletedType 2 Diabetes MellitusUnited States
-
AstraZenecaEli Lilly and CompanyCompletedType 2 DiabetesUnited States
-
University at BuffaloAmylin Pharmaceuticals, LLC.Completed